Literature DB >> 12442257

The spectrum of endogenous human chromogranin A-derived peptides identified using a modified proteomic strategy.

David F Orr1, Tianbao Chen, Anders H Johnsen, Rod Chalk, Keith D Buchanan, James M Sloan, Pingfan Rao, Chris Shaw.   

Abstract

The hypothesis that chromogranin A (CgA), a protein of neuroendocrine cell secretory granules, may be a precursor of biologically active peptides, rests on observed activities of peptide fragments largely produced by exogenous protease digestion of the bovine protein. Here we have adopted a modified proteomic strategy to isolate and characterise human CgA-derived peptides produced by endogenous prohormone convertases. Initial focus was on an insulinoma as previous studies have shown that CgA is rapidly processed in pancreatic beta cells and that tumours arising from these express appropriate prohormone convertases. Eleven novel peptides were identified arising from processing at both monobasic and dibasic sites and processing was most evident in the C-terminal domain of the protein. Some of these peptides were identified in endocrine tumours, such as mid-gut carcinoid and phaeochromocytoma, which arise from endocrine cells of different phenotype and in different anatomical sites. Two of the most interesting peptides, GR-44 and ER-37, representing the C-terminal region of CgA, were found to be amidated. These data would imply that the intact protein is C-terminally amidated and that these peptides are probably biologically active. The spectrum of novel CgA-derived peptides, described in the present study, should provide a basis for biological evaluation of authentic entities.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12442257     DOI: 10.1002/1615-9861(200211)2:11<1586::AID-PROT1586>3.0.CO;2-K

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  6 in total

1.  Snapshot peptidomics of the regulated secretory pathway.

Authors:  Kazuki Sasaki; Yoshinori Satomi; Toshifumi Takao; Naoto Minamino
Journal:  Mol Cell Proteomics       Date:  2009-03-31       Impact factor: 5.911

2.  Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies.

Authors:  Rafael Molina; Elias Alvarez; Angeles Aniel-Quiroga; Maria Borque; Belen Candás; Antonio Leon; Rafael M Poyatos; Montserrat Gelabert
Journal:  Tumour Biol       Date:  2010-08-21

3.  Mass spectrometry-based neuropeptidomics of secretory vesicles from human adrenal medullary pheochromocytoma reveals novel peptide products of prohormone processing.

Authors:  Nitin Gupta; Steven J Bark; Weiya D Lu; Laurent Taupenot; Daniel T O'Connor; Pavel Pevzner; Vivian Hook
Journal:  J Proteome Res       Date:  2010-10-01       Impact factor: 4.466

4.  Cathepsin L colocalizes with chromogranin a in chromaffin vesicles to generate active peptides.

Authors:  Nilima Biswas; Juan L Rodriguez-Flores; Maite Courel; Jiaur R Gayen; Sucheta M Vaingankar; Manjula Mahata; Justin W Torpey; Laurent Taupenot; Daniel T O'Connor; Sushil K Mahata
Journal:  Endocrinology       Date:  2009-04-16       Impact factor: 4.736

5.  A novel bioengineered fragment peptide of Vasostatin-1 exerts smooth muscle pharmacological activities and anti-angiogenic effects via blocking VEGFR signalling pathway.

Authors:  Ran Wei; Qiushuang Wu; Nana Ai; Lei Wang; Mei Zhou; Chris Shaw; Tianbao Chen; Richard Dequan Ye; Wei Ge; Shirley W I Siu; Hang Fai Kwok
Journal:  Comput Struct Biotechnol J       Date:  2021-05-03       Impact factor: 7.271

6.  Striking Oxygen Sensitivity of the Peptidylglycine α-Amidating Monooxygenase (PAM) in Neuroendocrine Cells.

Authors:  Peter D Simpson; Betty A Eipper; Maximiliano J Katz; Lautaro Gandara; Pablo Wappner; Roman Fischer; Emma J Hodson; Peter J Ratcliffe; Norma Masson
Journal:  J Biol Chem       Date:  2015-08-19       Impact factor: 5.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.